Document Detail

The fetal origins of the metabolic syndrome: can we intervene?
MedLine Citation:
PMID:  23029616     Owner:  NLM     Status:  MEDLINE    
Epidemiological studies have suggested that metabolic programming begins during fetal life and adverse events in utero are a critical factor in the etiology of chronic diseases and overall health. While the underlying molecular mechanisms linking impaired fetal development to these adult diseases are being elucidated, little is known about how we can intervene early in life to diminish the incidence and severity of these long-term diseases. This paper highlights the latest clinical and pharmaceutical studies addressing how dietary intervention in fetal and neonatal life may be able to prevent aspects of the metabolic syndrome associated with IUGR pregnancies.
Noelle Ma; Daniel B Hardy
Related Documents :
19566556 - Pregnancy outcome in the setting of extremely low first trimester papp-a levels.
12063436 - Down's syndrome screening in twin pregnancies by nuchal translucency measurement. curre...
9316126 - Combining ultrasound and biochemistry in first-trimester screening for down's syndrome.
6849846 - Feto-maternal haemorrhage as a cause of fetal morbidity and mortality.
3608376 - The influence of pregnancy on drug action: concentration-effect modelling with proprano...
952196 - Pregnancy and progeny in rats treated with prostaglandin a.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-09-17
Journal Detail:
Title:  Journal of pregnancy     Volume:  2012     ISSN:  2090-2735     ISO Abbreviation:  J Pregnancy     Publication Date:  2012  
Date Detail:
Created Date:  2012-10-02     Completed Date:  2013-06-03     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  101553823     Medline TA:  J Pregnancy     Country:  Egypt    
Other Details:
Languages:  eng     Pagination:  482690     Citation Subset:  IM    
Departments of Physiology and Pharmacology, and the Department of Obstetrics & Gynecology, The University of Western Ontario, London, ON, Canada N6A 5C1; The Children's Health Research Institute, The Lawson Health Research Institute, London, ON, Canada N6A 4V2.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antioxidants / therapeutic use
Ascorbic Acid / therapeutic use
Diet Therapy
Dietary Supplements
Fatty Acids, Omega-3 / therapeutic use
Fetal Growth Retardation / etiology,  metabolism,  prevention & control*
Folic Acid / therapeutic use
Hypoglycemic Agents / therapeutic use
Melatonin / therapeutic use
Metabolic Syndrome X / etiology,  metabolism,  prevention & control*
Micronutrients / therapeutic use
Peptides / therapeutic use
Prenatal Exposure Delayed Effects / etiology,  metabolism,  prevention & control*
Prenatal Nutritional Physiological Phenomena
Stilbenes / therapeutic use
Venoms / therapeutic use
Reg. No./Substance:
0/Antioxidants; 0/Fatty Acids, Omega-3; 0/Hypoglycemic Agents; 0/Micronutrients; 0/Peptides; 0/Stilbenes; 0/Venoms; 141732-76-5/exenatide; 50-81-7/Ascorbic Acid; 59-30-3/Folic Acid; 73-31-4/Melatonin; Q369O8926L/resveratrol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dynamic associations of change in physical activity and change in cognitive function: coordinated an...
Next Document:  Barriers and facilitators to community mobility for assistive technology users.